Lishan Su1. 1. Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. lsu@med.unc.edu.
Abstract
PURPOSE OF REVIEW: Recent findings on the critical pathogenic role of type 1 interferons (IFN-I) in HIV-1 persistence in humanized mice suggest that inhibiting IFN-I signaling transiently will reverse HIV-induced inflammatory diseases and rescue anti-HIV immunity to control HIV-1 reservoirs. RECENT FINDINGS: In both humanized mice and in monkeys, IFN-I signaling is functionally defined to play an important role in suppressing early HIV-1 and SIV infection. During persistent infection in humanized mice, however, IFN-I signaling is revealed to induce T cell depletion and impairment. Interestingly, in HIV-infected mice with effective combination antiretroviral therapy (cART), blocking IFN-I signaling reverses HIV-induced inflammation, rescues anti-HIV T cells, and reduces HIV-1 reservoirs. These findings functionally define the role of IFN-I in HIV-1 reservoir persistence and suggest that blocking IFN-I signaling will provide a novel therapeutic strategy to (i) reverse inflammation-associated diseases in HIV patients under cART, (ii) rescue host anti-HIV immunity, and (iii) reduce or control HIV-1 reservoirs.
PURPOSE OF REVIEW: Recent findings on the critical pathogenic role of type 1 interferons (IFN-I) in HIV-1 persistence in humanized mice suggest that inhibiting IFN-I signaling transiently will reverse HIV-induced inflammatory diseases and rescue anti-HIV immunity to control HIV-1 reservoirs. RECENT FINDINGS: In both humanized mice and in monkeys, IFN-I signaling is functionally defined to play an important role in suppressing early HIV-1 and SIV infection. During persistent infection in humanized mice, however, IFN-I signaling is revealed to induce T cell depletion and impairment. Interestingly, in HIV-infectedmice with effective combination antiretroviral therapy (cART), blocking IFN-I signaling reverses HIV-induced inflammation, rescues anti-HIV T cells, and reduces HIV-1 reservoirs. These findings functionally define the role of IFN-I in HIV-1 reservoir persistence and suggest that blocking IFN-I signaling will provide a novel therapeutic strategy to (i) reverse inflammation-associated diseases in HIV patients under cART, (ii) rescue host anti-HIV immunity, and (iii) reduce or control HIV-1 reservoirs.
Entities:
Keywords:
HIV-1 reservoirs; IFNAR; ISG; Inflammation; T cell exhaustion; pDC
Authors: L R Deyton; R E Walker; J A Kovacs; B Herpin; M Parker; H Masur; A S Fauci; H C Lane Journal: N Engl J Med Date: 1989-11-02 Impact factor: 91.245
Authors: Hannes Kalscheuer; Nichole Danzl; Takashi Onoe; Ted Faust; Robert Winchester; Robin Goland; Ellen Greenberg; Thomas R Spitzer; David G Savage; Hiroyuki Tahara; Goda Choi; Yong-Guang Yang; Megan Sykes Journal: Sci Transl Med Date: 2012-03-14 Impact factor: 17.956
Authors: Doron Levin; William M Schneider; Hans-Heinrich Hoffmann; Ganit Yarden; Alberto Giovanni Busetto; Ohad Manor; Nanaocha Sharma; Charles M Rice; Gideon Schreiber Journal: Sci Signal Date: 2014-05-27 Impact factor: 8.192
Authors: Victoria P Strouvelle; Dominique L Braun; Valentina Vongrad; Alexandra U Scherrer; Yik Lim Kok; Roger D Kouyos; Marcel Stöckle; Andri Rauch; Katharine Darling; Matthias Hoffmann; Karin J Metzner; Huldrych F Günthard Journal: J Infect Dis Date: 2018-05-25 Impact factor: 7.759
Authors: Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995